Return to homepagePandemic Pact

Virus Wars: Are E3-Targeted Therapies A New Hope?

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:2 publications

Grant number: MR/T043482/1

Grant search

Key facts

  • Disease

    N/A

  • Start & end year

    2021
    2025

  • Known Financial Commitments (USD)

    $1,679,014.46

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Dr. Adam Fletcher

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Glasgow

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Alternative splicing broadens antiviral diversity at the human OAS2 locus.

ATP functions as a pathogen-associated molecular pattern to activate the E3 ubiquitin ligase RNF213.